Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I’d now like to turn the call over to Amneal’s Head of ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

Second, in GLP-1s, we continue to advance our partnership with Metsera in the weight loss and obesity space, which represents a new integrated business model to drive innovation at scale in GLP-1s.

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Mounjaro, initially for type 2 diabetes, gains popularity for weight loss, yet users report severe side effects. Ellie Marie, after losing nearly five stone, discontinued Mounjaro due to hair loss ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Snacking doesn’t have to derail your weight loss goals. Women's weight loss expert Jade Poyser shares 7 under-300 calorie snacks that helped her lose 10 kg. Weight loss expert reveals 7 ...